ClinicalTrials.gg
RecruitingNCT04315727Updated Nov 29, 2023

Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings

An interventional study of WGS Diagnostic Blood take for genetic diagnostic. and Hair collection in Rare Diseases and Genetic Predisposition to Disease, sponsored by University Hospital Tuebingen. Recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Study summary

The GENOME + project will enroll patients (n = ca. 100) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism. As well healthy parents of those affected for trio analysis (exception of one parent is not available for the study).

Read the detailed description

In the GENOME+ study (monocentric, prospective, open-label diagnostic study), patients with molecularly undiagnosed diseases will diagnostically be analyzed by means of omics technologies or re-analyzed using existing datasets. The following questions will be leading the study:

Primary:

  • Identification of the molecular causes of unclear rare diseases

Secondary:

  • Improve number of diagnoses for patients with rare diseases
  • Further characterization of the identified putative disease causes
  • Increase number of patients receiving appropriate therapy after successful diagnosis.

In addition, healthy parents of the subjects may be included in the study to perform parent-child (trio) analyses.

In addition, phenotype and omics data will be shared within the University Hospital Tübingen, Germany and with external collaborators to improve the diagnostic rate of the patients included in the study.

Storage of blood or tissue samples is not primary goal of this project, but may be necessary for further analyses.

02

Conditions studied

  • Rare Diseases
  • Genetic Predisposition to Disease

Keywords

  • Rare Diseases
  • Genetic Predisposition
  • Whole Exome Sequencing
  • Whole Genome Sequencing (WGS)
  • WGS-trio analysis
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 339 interventional studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unclear diagnosis
  • Suspected genetic cause of the disease
  • Previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism
  • Healthy parents of those affected for trio analysis (exception of one parent is not available for the study)

Exclusion criteria

Exclusion Criteria:

  • Missing of the patient and her/his parents
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Study population

    Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies. Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation).

    Genetic: WGS Diagnostic Blood take for genetic diagnostic. · Genetic: Hair collection

Interventions

  • GeneticWGS Diagnostic Blood take for genetic diagnostic.

    Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).

  • GeneticHair collection

    Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation

06

What researchers measure

Primary outcomes

  1. Identification of the molecular causes of unclear rare diseases

    Number of molecular causes

    Time frame: Day 1

Secondary outcomes

  1. Diagnoses for patients with rare diseases

    Number of diagnoses for patients with rare diseases

    Time frame: Day 1

  2. Molecular characterization of putative disease causes

    Identify molecular characterization of the putative disease causes

    Time frame: Day 1

  3. Patients receiving appropriate therapy after successful diagnosis

    Number of patients receiving appropriate therapy after successful diagnosis

    Time frame: Day 1

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The GENOME+ study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts

Supporting information: Analytic code

Time frame: Data will become available after analysis and unlimited.

Access criteria: Authorized users within the participating organizations

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Jul 2024, 41 months after the start.

Of 36 interventional studies with no phase under Rare Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 41 months is above that.

Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2020
First posted
Mar 19, 2020
StartActual
Feb 1, 2021
Primary completionEst.
Jul 2024
CompletionEst.
Dec 2024
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04315727
Responsible party
Sponsor
First posted
Mar 19, 2020
Start date
Feb 1, 2021
Primary completion
Jul 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Nov 29, 2023

Study contacts

Olaf Rieß, Prof. Dr.
Contact
olaf.riess@med.uni-tuebingen.de
+49 7071 29 ext. 72323
Andreas Dufke, PD Dr.
Contact
andreas.dufke@med.uni-tuebingen.de
+49 7071 29 ext. 72190
Olaf Rieß
study director · University Hospital Tübingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion